 |
| (사진= 대웅제약) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Daewoong Pharmaceutical announced on the 15th that sales on a separate basis rose 10.1% year-on-year to KRW 1.1613 trillion last year. Operating profit rose 11.0% year-on-year to 106 billion won and net profit rose 123.9% to 80.1 billion won over the same period.
Consolidated sales of 1.28 trillion won and operating profit of 95.8 billion won in 2022. The figure is up 11.0 percent and 7.8 percent, respectively, from a year earlier. Net profit rose 140.8% year-on-year to 76.1 billion won.
Sales of Nabota, a botulinum toxin drug, rose 78.5% year-on-year to 142 billion won. Nabota is raising 77% of its sales overseas. Nabota's overseas sales doubled to 109.9 billion won last year from a year earlier. In particular, sales in the United States increased by 49% in a year.
Sales in the over-the-counter medicine sector reached KRW 127.7 billion last year.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
